Empiriko’s Interconnected Platforms Improve Clinical Outcomes
By accelerating drug research and development (Biomimiks™)
Providing personalized diagnostics at the point-of-care (Personalized Metabolic Fingerprint™ device)
Providing actionable analytics to improve outcomes for individuals and populations
Biomimiks™ Platform - Future of Drug Development
Chemosynthetic liver in vitro technology
Accelerates development of more effective, affordable and safer drugs without the need for animal testing.
The synergies created by connecting the data flow between these two platforms create a series of opportunities to cost-effectively accelerate drug development, improve clinical outcomes, and deliver the power of precision medicine to individuals and populations.
Personalized Metabolic Fingerprint™ Device Next Generation of Precision Medicine at Point-of-Care
Point-of-care assessment of chemical (drug), immunologic, and genetic
biomarkers for early disease detection and therapeutic monitoring.
